Expert Interview
A Second Look: Discussing recent updates from EHA on menin inhibitors, including DSP-5336, JNJ-6617 in combo with Ven/Aza in r/r AML, and revumenib with the same combo but in newly diagnosed AML.
Ticker(s): KURA, JNJ, SNDXInstitution: Mount Sinai
- Assistant Professor of Medicine, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, MDS & Leukemia Groups
- Focus on novel therapeutic drug development in MDS, MPN, AML, ALL
- Translational Research on the Impact of the immune microenvironment on disease pathogenesis
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
